Insulin-leptin-visceral fat relation during weight loss.
BACKGROUND
The relation between insulin-leptin-visceral fat axis during weight loss has not been studied previously.


OBJECTIVE
To evaluate the insulin, leptin, and abdominal adiposity relation during weight loss in patients with upper body obesity.


METHODS
Twenty volunteers (7 men, 13 women) with mean age 50.6+/-6.3 (SD) and upper body obesity (weight 105.4+/-12.3 kg, BMI 35.9+/-2.5 kg/m2) were recruited. Participants were enrolled in a one-arm clinical study using a calorie-deficient diet and an escalating dose regimen of sibutramine, starting with 5 mg daily and increasing in 5-mg increments to 20 mg per day. Body weight, insulin, leptin, glucose, lipids, abdominal computed tomography (CT), and total body electrical conductance (TOBEC) were measured serially at weeks 0, 4, 8, 12, and 24.


RESULTS
Eighteen patients completed the 6-month study: one man and one woman discontinued because of adverse events. With diet and sibutramine, body weight was significantly and continuously reduced throughout the 6-month study. There was a 16.0% (p = 0.0001) reduction in body weight (p < 0.001) and 22.5% (p = 0.0001) decrease in total body fat mass. Abdominal CT scans showed a 28.3% (p = 0.0001) reduction in total abdominal fat, a 26.0% (p = 0.0001) reduction in subcutaneous fat (p < 0.001), and a 31.0% (p = 0.0003) reduction in visceral fat (p < 0.001). There was a 32.0% (p = 0.0008) reduction in leptin levels and 37.9% (p = 0.0001) reduction in insulin levels between baseline and week 4, but no further significant reduction in leptin and insulin levels was observed for the duration of the study. There was a significant correlation between insulin and leptin concentrations throughout the study (p = 0.0001). Leptin was presented as a function of insulin measured at the same time. Significant associations between visceral abdominal fat, subcutaneous fat, and leptin were also observed.


CONCLUSIONS
In this study, we found that leptin and insulin were related in weight loss. The data suggest that insulin may act as a strong regulator of leptin secretion during weight loss and that circulating leptin levels can be predicted by insulin level. Using sibutramine in conjunction with hypocaloric diet reduced body weight and decreased fat mass significantly. Visceral and subcutaneous abdominal fat depots were shown to decrease. Whether sibutramine exerts any selective reduction of visceral abdominal fat as opposed to total body fat mass will require further clinical investigation.
Yip
I
I
Center for Human Nutrition, School of Medicine, University of California at Los Angeles, 90095-1742, USA. iyip@mednet.ucla.edu
Go
V L
VL
Hershman
J M
JM
Wang
H J
HJ
Elashoff
R
R
DeShields
S
S
Liu
Y
Y
Heber
D
D
D000273:Adipose Tissue / Q000473:pathology*; D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use; D003503:Cyclobutanes / Q000627:therapeutic use; D004038:Diet, Reducing; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood*; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy / Q000473:pathology*; D013997:Time Factors; D014781:Viscera; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology*
D001067:Appetite Depressants; D003503:Cyclobutanes; D007328:Insulin; D020738:Leptin; C058254:sibutramine